Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Needle-free Triamcinolone Acetonide for Cutaneous Lymphoma
NCT05106192Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Apr 2022
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Open-label trial (2 cohorts), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Pain measurement at 1.5 hours. Planned start Apr 2022; status: withdrawn.
Beyond the preview
Go deeper on NCT05106192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106192.